BioCentury
ARTICLE | Clinical News

Erbitux cetuximab: Phase III data

May 2, 2016 7:00 AM UTC

Top-line data from the open-label, Chinese Phase III TAILOR trial in 397 patients with wild-type Ras mCRC showed that first-line treatment with Erbitux plus FOLFOX-4 chemotherapy met the primary endpoint of improving PFS vs. FOLFOX-4 alone. Merck said it will work with Chinese regulatory authorities to make Erbitux as a first-line treatment of mCRC available as soon as possible. Erbitux is approved in over 90 countries to treat CRC and squamous cell carcinoma of the head and neck (SCCHN). ...